ARTICLE | Clinical News
XL184: IND submitted
June 20, 2005 7:00 AM UTC
EXEL submitted an IND to begin in the third quarter an open-label, dose-escalation, U.S. Phase I trial in patients. ...
Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
EXEL submitted an IND to begin in the third quarter an open-label, dose-escalation, U.S. Phase I trial in patients. ...